ArticleDiscover oncology2025
Relationship between the BRAF-V600E variant allele frequency and clinicopathological characteristics of papillary thyroid carcinoma and its clinical application.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the relationship between B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E variant allele frequency (VAF) and clinicopathological characteristics in papillary thyroid carcinoma (PTC) patients. To investigate the risk factors for central lymph node metastasis (cLNM) in PTC and establish a predictive model.
methodTissue specimens of 143 PTC patients who underwent thyroidectomy at the Department of Thyroid Surgery, the Third Affiliated Hospital of Nanjing Medical University from January 2018 to December 2023 were collected, and BRAF-V600E VAF was detected. According to the median VAF, patients were divided into low and high-frequency mutation group. The relationship between BRAF-V600E VAF and clinicopathological characteristics of the two groups was analyzed by using χ2 test, T test and Mann-Whitney U test. Patients were divided into two groups according to the presence or absence of cLNM. The clinicopathological characteristics of the two groups were compared. The multivariate logistic regression analysis was used to identify the independent risk factors for cLNM and a predictive nomogram model was established. The predictive efficacy was evaluated by the area under the curve (AUC).
resultsBRAF-V600E VAF was associated with T stage, N stage, primary lesion size, number of metastatic lymph nodes, invasion, and risk of intermediate-to-high risk recurrence in PTC (P < 0.05), but not with age, sex, TNM stage, multifocus, unilateral or bilateral (P > 0.05). Multivariate analysis showed that sex, multifocus and BRAF-V600E VAF were independent risk factors for cLNM in PTC (P < 0.05). The independent risk factors were used to establish a nomogram predictive model. The AUC value of this model was 0.778 (P < 0.05).
conclusionBRAF-V600E VAF is associated with high invasive characteristics of PTC. The predictive model developed in this study can effectively predict cLNM in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.